Skip to main content

York Charles N II's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 17, 2023

Accession no.
0001209191-23-055896
Filed
Nov 17, 2023
Trade date
Nov 15-16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $11.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
York Charles N IICIK 0001655962Officer (COO, CFO and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2023Common StockMOption exerciseAcquired+1,375–F1–268,876Direct
Nov 15, 2023Common StockMOption exerciseAcquired+2,250–F1–271,126Direct
Nov 16, 2023Common StockSSaleDisposed−956$11.69−$11,175.64270,170Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2023Common StockMOption exerciseDisposed−1,375$0.00$011,000Direct
Nov 15, 2023Common StockMOption exerciseDisposed−2,250$0.00$027,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)